Geode Capital Management LLC raised its stake in shares of Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) by 9.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 163,242 shares of the company’s stock after acquiring an additional 14,199 shares during the quarter. Geode Capital Management LLC’s holdings in Unity Biotechnology were worth $240,000 at the end of the most recent reporting period.
Separately, Ballentine Partners LLC purchased a new stake in shares of Unity Biotechnology during the 3rd quarter valued at $84,000. Hedge funds and other institutional investors own 29.49% of the company’s stock.
Wall Street Analyst Weigh In
Separately, Chardan Capital started coverage on Unity Biotechnology in a report on Friday. They set a “buy” rating and a $6.00 price objective for the company.
Unity Biotechnology Trading Down 3.9 %
Shares of UBX opened at $1.72 on Tuesday. Unity Biotechnology, Inc. has a 12 month low of $0.94 and a 12 month high of $2.02. The stock has a fifty day moving average price of $1.18 and a 200-day moving average price of $1.36. The firm has a market cap of $28.98 million, a PE ratio of -1.31 and a beta of 0.80.
Unity Biotechnology (NASDAQ:UBX – Get Free Report) last issued its earnings results on Monday, November 4th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. As a group, research analysts forecast that Unity Biotechnology, Inc. will post -1.49 EPS for the current year.
About Unity Biotechnology
Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.
Featured Articles
- Five stocks we like better than Unity Biotechnology
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- When to Sell a Stock for Profit or Loss
- Delta Can Fly to New Highs in 2025; Here’s Why
Want to see what other hedge funds are holding UBX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report).
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
